News Headlines Article

Pfizer Alzheimer’s drug fails in study
USA Today

A promising Alzheimer’s disease drug Pfizer Inc. and a partner are developing failed to work in a late-stage study, a startling disappointment after the potential blockbuster kept symptoms from worsening for a year in a prior test. Pfizer and partner Medivation Inc. said Wednesday that the experimental drug, Dimebon, failed to meet its primary and secondary goals — improving thinking ability and overall daily function over six months in patients with mild to moderate Alzheimer’s disease.